“…It therefore seemed interesting to replace the ubiquitous carboxamide, present in the R 1 side chain of both β-lactams and their boronic acid mimics, by a sulfonamide (Scheme ). Whereas sulfonamide replacements for carboxamides date back to the seminal synthetic work of Sheehan in the 1950s, these derivatives were never used clinically and, as far as we know, have never been explored among β-lactamase inhibitors previous to this year. Very recent work by Tan et al at Merck revealed two arylsulfonamide boronic acids with activity in the low micromolar range (IC 50 a Abbreviations: LE, ligand efficiency (=(Δ G binding (kcal/mol))/(number of non-hydrogen atoms)); PDB, Protein Data Bank; IC 50 , half-maximal inhibitory concentration; SAR, structure−activity relationship; MIC, minimum inhibitory concentration; CLSI, Clinical and Laboratory Standards Institute; CAZ, ceftazidime; FOX, cefoxitin; THF, tetrahydrofuran; TLC, thin layer chromatography. between 0.57 and 5.6 μM) against five different β-lactamases …”